These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
559 related items for PubMed ID: 21839237
1. Everolimus in clinical practice in long-term liver transplantation: an observational study. Casanovas T, Argudo A, Peña-Cala MC. Transplant Proc; 2011; 43(6):2216-9. PubMed ID: 21839237 [Abstract] [Full Text] [Related]
2. Conversion to everolimus in liver transplant patients with renal dysfunction. Pérez T, Segovia R, Castro L, Roblero JP, Estela R. Transplant Proc; 2011; 43(6):2307-10. PubMed ID: 21839260 [Abstract] [Full Text] [Related]
3. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience. Santos SM, Carlos CM, Cabanayan-Casasola CB, Danguilan RA. Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603 [Abstract] [Full Text] [Related]
4. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction. Castroagudín JF, Molina E, Romero R, Otero E, Tomé S, Varo E. Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140 [Abstract] [Full Text] [Related]
5. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, Rostaing L, De Carlis L, Saliba F, Nevens F. Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150 [Abstract] [Full Text] [Related]
6. Indications and management of everolimus after liver transplantation. Bilbao I, Sapisochin G, Dopazo C, Lazaro JL, Pou L, Castells L, Caralt M, Blanco L, Gantxegi A, Margarit C, Charco R. Transplant Proc; 2009 Oct; 41(6):2172-6. PubMed ID: 19715864 [Abstract] [Full Text] [Related]
11. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L. Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508 [Abstract] [Full Text] [Related]
12. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology. Gabardi S, Baroletti SA. Pharmacotherapy; 2010 Oct; 30(10):1044-56. PubMed ID: 20874042 [Abstract] [Full Text] [Related]
13. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study. Holdaas H, Rostaing L, Serón D, Cole E, Chapman J, Fellstrøm B, Strom EH, Jardine A, Midtvedt K, Machein U, Ulbricht B, Karpov A, O'Connell PJ, ASCERTAIN Investigators. Transplantation; 2011 Aug 27; 92(4):410-8. PubMed ID: 21697773 [Abstract] [Full Text] [Related]